Retrospective study for significance of polymorphisms of UGT1A1 for Irinotecan toxicities in advanced cancer patients who received Irinotecan chemotherapy

Retrospective study for significance of polymorphisms of UGT1A1 for Irinotecan toxicities in advanced cancer patients who received Irinotecan chemotherapy - Retrospective study of polymorphisms of UGT1A1 and Irinotecan toxicities

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002884

Enrollment

Registered

2010-01-25

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advenced cancer patients who received Irinotecan containing chemotherapy

Exclusion criteria

Exclusion criteria: n/a

Design outcomes

Primary

Measure	Time frame
Severe adverse effects of grade 3 or severer neutropenia and/or diarrhea after receiving Irinotecan containing chemotherapy	—

Countries

Japan

Contacts

Public ContactShoko Akiyama

Tohoku University Hospital Clinical Oncology

s-ikeda@idac.tohoku.ac.jp022-717-8543

Outcome results